The U.S. Food and Drug Administration approved ibrutinib (Imbruvica; Pharmacyclics) plus rituximab (Rituxan) for the treatment of adult patients with Waldenstrom's macroglobulinemia (WM). Read full press release. 

The U.S. Food and Drug Administration approved moxetumomab pasudoltox-tdfk (Lumoxiti; AstraZeneca Pharmaceuticals), a CD22-directed cytotoxin indicated for adult patients with relapased or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). Read full press release. 

The U.S. Food and Drug Administration approved encorafenib and binimetinib (Braftovi and Mektovi; Array BioPharma) in combination for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, as detected by an FDA-approved test. Read full press release.

The U.S. Food and Drug Administration approved bevacizumab (Avastin; Genentech) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplat and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection. Read full press release. 

The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda; Merck) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy. Read full press release.

The U.S. Food and Drug Administration granted regular approval to venetoclax (Venclexta; AbbVie and Genentech) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Read full press release.

The U.S. Food and Drug Administration approved tisagenlecleucel (Kymriah; Novartis), a CD19-directed genetically modified autologous T-cell immunotherapy, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Read full press release. 

The U.S. Food and Drug Administration approved rucaparib (Rubraca; Clovis Oncology), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Read full press release.

The U.S. Food and Drug Administration osimertinib (Tagrisso; AstraZeneca) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. Read full press release.

The U.S. Food and Drug Administration granted regular approval to dabrafenib (Tafinlar; Novartis) and trametinib (Mekinist; Novartis) in combination for the adjuvant treatment of patients with melanoma with BRAF 600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. Read full press release.